Revolution Medicines, Inc. Quarterly Nonoperating Income (Expense) in USD from Q1 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Revolution Medicines, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q1 2019 to Q3 2024.
  • Revolution Medicines, Inc. Nonoperating Income (Expense) for the quarter ending September 30, 2024 was $19.4M, a 77.4% increase year-over-year.
  • Revolution Medicines, Inc. Nonoperating Income (Expense) for the twelve months ending September 30, 2024 was $86.5M, a 158% increase year-over-year.
  • Revolution Medicines, Inc. annual Nonoperating Income (Expense) for 2023 was $47.3M, a 417% increase from 2022.
  • Revolution Medicines, Inc. annual Nonoperating Income (Expense) for 2022 was $9.15M, a 898% increase from 2021.
  • Revolution Medicines, Inc. annual Nonoperating Income (Expense) for 2021 was $917K, a 57.7% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $86.5M $19.4M +$8.48M +77.4% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 $78M $23.4M +$12.9M +123% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 $65.1M $24.9M +$17.8M +252% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $47.3M $18.8M +$13.7M +270% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-26
Q3 2023 $33.6M $10.9M +$8.04M +277% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 $25.5M $10.5M +$9.63M +1111% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 $15.9M $7.06M +$6.76M +2237% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $9.15M $5.08M +$4.84M +2043% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-26
Q3 2022 $4.31M $2.91M +$2.68M +1204% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 $1.63M $867K +$631K +267% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $998K $302K +$81K +36.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 $917K $237K -$1K -0.42% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-26
Q3 2021 $918K $223K -$107K -32.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 $1.03M $236K -$475K -66.8% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $1.5M $221K -$667K -75.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $2.17M $238K -$357K -60% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-27
Q3 2020 $2.52M $330K -$411K -55.5% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $2.94M $711K +$269K +60.9% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-11
Q1 2020 $2.67M $888K +$583K +191% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 $2.08M $595K Oct 1, 2019 Dec 31, 2019 10-K 2022-02-28
Q3 2019 $741K Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 $442K Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 $305K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.